Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)

- New Positive Phase 2 Results in Metastatic Triple Negative Breast Cancer Indicate That Use of Trilaciclib in Combination with a TROP2 ADC May Be Associated with Improved Median OS Compared to...

Related Keywords

Los Angeles ,California ,United States ,American ,Lasika Seneviratne ,Raj Malik ,Sacituzumab Govitecan ,Linkedin ,European Society For Medical Oncology ,Corporate Communications ,American Society Of Clinical Oncology ,Los Angeles Cancer Network ,Research Triangle Park ,American Cancer Society ,Nasdaq ,Exchange Commission ,Therapeutics Inc ,Association Of Outcomes ,Positive Phase ,Metastatic Triple Negative Breast Cancer ,Indicate That Use ,Improved Median ,Historical Data ,More Comparable Patient Population Showed ,Approximately Six Month Improvement ,Patients Receiving Trilaciclib ,Target Effect ,Trilaciclib Reduces Rates ,Multiple Adverse Events Associated ,Clinical Oncology ,Breast Cancer Metastatic ,Updated Phase ,Chief Medical Officer ,Chief Scientific Officer ,Research Division ,Survival Analyses ,European Society ,Medical Oncology ,Breast Cancer ,Chief Medical ,Triple Negative Breast Cancer ,Private Securities Litigation Reform Act ,Investor Relations ,Randomized Phase ,Human Epidermal Growth Factor Receptor ,Trophoblast Cell Surface Antigen ,